Verdict: Side-by-side breakdown using the Bull Rankings model. CORT scored 53.2, HALO scored 83.1 — HALO leads.
Compare another set
CORT
Corcept Therapeutics Incorporated
Biotechnology · Quality-Growth
53.2
$121.19 · $13.1B
fundamentals as of
Score gap
29.9
HALO leads
HALO
Halozyme Therapeutics, Inc.
Biotechnology · Quality-Growth
83.1
$110.42 · $12.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthHALO+41.2%
Highest qualityHALO89 / 100
Largest discount to fair valueHALO-40%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
CORT
stronger →← stronger
HALO
47
Qualityreturns · margins · balance sheet
89
81
Growthrevenue & earnings expansion
98
40
Valuevaluation vs sector peers
66
HALO is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
CORT
HALO
$107mC
FCF
$806mC+
+12.8%B+
Rev
+41.2%A
0.01A-
D/E
—
15.8xC
P/S
—
0.81B+
PEG
1.47B
—
P/E
32.3xC+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
CORT
HALO
526% above
Price vs fair valuelower is cheaper
40% below
>60%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~2%/yr
-86%
1-yr DCF upside
+27%
-84%
5-yr DCF upside
+66%
-80%
10-yr DCF upside
+146%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
CORT
Why this score
Diluting shareholders
HALO
Why this score
Buying back stock
Durable high returns
The companies
CORTCorcept Therapeutics Incorporated
Biotechnology · $121.19 · beta 0.40
Why now
Biotechnology · market cap $13.1b. 4% off the 52-week high of $126.38. Revenue growing +13%, comfortably above the S&P median. PEG 0.81 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $141.00 (implying +16% upside).
Moat
FCF converts 197% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
P/S 15.8x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HALOHalozyme Therapeutics, Inc.
Biotechnology · $110.42 · beta 0.88
Why now
Biotechnology · market cap $12.5b. 6% off the 52-week high of $116.85. Revenue growing +41% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $101.75 (implying -8% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where CORT and HALO diverge
On the headline score the gap is 29.9 points in favor of HALO. The widest single difference is Quality, where HALO leads by 42.2 points.
QualityCORT 46.7 · HALO 88.9HALO +42.2
ValueCORT 39.9 · HALO 65.9HALO +26.0
GrowthCORT 81.0 · HALO 98.0HALO +17.0
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is HALO or CORT the better stock?
HALO scores higher: HALO 83.1, CORT 53.2 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do HALO and CORT differ most?
The widest gap is quality, where HALO leads by 42 points on the 0–100 pillar scale. HALO leads all three pillars, so the gap is broad rather than a single-measure difference.
How are HALO and CORT scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.